All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .
Biochem/physiol Actions
CD93 is a 100kDa multidomain and multi-functional transmembrane glycoprotein. It is expressed by myeloid cell lineages in peripheral blood (PB) mononuclear cells. It mediates the change in growth and morphological abnormalities, and the initiation of apoptosis. In cervical squamous cell carcinoma, it restricts cell viability, migration, and proliferation via the p38 MAPK signaling pathway. CD93 has been suggested as a potential biomarker for coronary artery disease (CAD) and myocardial infarction (MI).
